Investor Sues $2.6B Allergy Drugmaker Over Nestle Deal
An investor in a $2.6 billion biopharmaceutical company that's making the first federally approved peanut allergy treatment for children alleged that the company left out key financial information in disclosures surrounding...To view the full article, register now.
Already a subscriber? Click here to view full article